To All:
The message that follows this message contains a copy of the abstract that Dr. Hensley, co-developer of Zicam, presented at the 5th International Symposium on Applied Bioinorganic Chemistry, 13-17 April 1999, in Corfu, Greece. Dr. Hensley presented on the 3rd day, Thursday, April 15, Session 3, Metal Based Drugs - Metals in Medicine, from 1930 to 1950 pm.
A website containing information about the conference is located at uoi.gr. Dr. Hensley and Dr. Davidson were invited to the conference after the organizers heard about Zicam. Since they were invited at such a late date, the organizers didn't update the online agenda so you won't find Dr. Hensley's name on the website. This is unfortunate, and I plan to follow up to see if the organizers will add his name to the online agenda. I do have a paper copy of the agenda that shows that Dr. Hensley presented during Session 3 at the time shown above.
The results of the clinical study described in the abstract are most compelling. You will notice that the duration and severity of cold symptoms decreased as the number of millimoles (mM) of ionic zinc increased. This, along with the p-value < 0.001, confirm with little doubt, that Zicam is responsible for reducing the duration of common cold symptoms to an average of 1.5 days. I am confident that the New England Journal of Medicine will publish the article given that the study results are so utterly compelling.
I have GumTech's permission to post the abstract and look forward to everyone's constructive comments, both positive and negative.
Disclaimer: Please note that I typed the abstract from a fax copy. While I compared it several times to the copy and found no differences, it may contain immaterial typographical errors. I believe that the typed copy in the next message is verbatim with the actual abstract.
Dan |
